Experts on AxSpA-IBD Treatment Weigh In on NSAIDs, Biologics
Experts are reevaluating the use of NSAIDs in patients with axial spondyloarthritis and inflammatory bowel disease. Research indicates that while NSAIDs may increase risks for Crohn's disease patients, there is no evidence of similar risks for those with ulcerative colitis. The discussion highlights the importance of tailored treatment strategies and the potential benefits of combination therapies and IL-23 inhibitors.
- ▪About 10% of patients with axial spondyloarthritis also have inflammatory bowel disease.
- ▪Research shows an increased risk for flares in Crohn's disease patients taking NSAIDs, but no evidence of risk in ulcerative colitis patients.
- ▪Clinicians are increasingly using combination therapies and considering IL-23 inhibitors for better treatment outcomes.
Opening excerpt (first ~120 words) tap to expand
TORONTO — Contrary to popular opinion — and some guidelines — nonsteroidal anti-inflammatory drugs (NSAIDs) may not always be contraindicated in patients with axial spondyloarthritis (axSpA) who have inflammatory bowel disease (IBD).“The [gastrointestinal] guidelines tell us not to use NSAIDs, but I think there are some patients in whom we can,” Adam Mayer, MD, assistant professor of internal medicine and pediatrics, Hackensack Meridian School of Medicine, Nutley, New Jersey, told Medscape Medical News.Mayer, whose research focuses on earlier detection and optimal treatment of axSpA in patients with IBD, discussed the management of such patients during the Spondyloarthritis Research and Treatment Network (SPARTAN) 2026 Annual Meeting.About 10% of patients with axSpA have IBD.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
